The u.S. companion animal health market size is projected to be USD 7.88 billion in 2025, USD 8.67 billion in 2026, and reach USD 13.91 billion by 2031, growing at a CAGR of 9.92% from 2026 to 2031. This report is Segmented by Animal Type (Dogs, Cats, Equine, Other Companion Animals), Product Type (Therapeutics, Diagnostics, Digital Health & Services), Indication (Infectious Diseases, Dand More), Distribution Channel (Veterinary Hospital & Clinic Pharmacies, and More). The Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
Cats are projected to grow at an 11.15% CAGR from 2026 to 2031, making them the fastest-growing segment in the United States companion animal health market. This growth is supported by species-specific innovations, such as a feline liquid biopsy prototype with 97% specificity for lymphoma detection and the launch of RapidRead Dental for Feline. Equine and other companion animals maintain stable demand through preventive care and specialized treatments.
Therapeutics accounted for 43.25% of the United States companion animal health market revenue in 2025, benefiting from new approvals and label expansions for chronic and specialty conditions. Key developments include VETMEDIN's clearance for preclinical myxomatous mitral valve disease and NUMELVI's approval for managing pruritus in dogs. The focus is shifting toward pain management, monoclonal antibodies, and chronic disease treatments.
Diagnostics is forecast to grow at a 12.75% CAGR from 2026 to 2031, becoming the fastest-growing product category. Clinics are adopting tools that streamline workflows, such as SDMA kidney biomarker testing integrated into Catalyst chemistry profiles. While digital health platforms are emerging, diagnostics stands out as a key driver of revenue growth through workflow integration.
U.S. Companion Animal Health Market Trends and Insights
Premiumization and Humanization of Pet Healthcare
The United States companion animal health market is experiencing a shift as households increasingly prioritize pets and invest in their care. By 2025, the pet industry spending reached USD 158 billion, with veterinary care contributing USD 41.4 billion, making it a key category. This trend drives demand for advanced diagnostics, chronic disease treatments, and specialty services, moving beyond routine wellness. Clinics are adopting comprehensive treatment plans, while manufacturers and service providers expand premium offerings in oncology, pain management, dermatology, and long-term monitoring.Pet Insurance Expansion and Financing-Led Care Acceptance
Pet insurance is becoming a critical driver of treatment acceptance in the United States companion animal health market. In 2025, direct premiums written reached USD 5.47 billion, reflecting double-digit growth. Expanding coverage enables pet owners to access advanced imaging, specialist referrals, and multi-drug protocols, particularly in high-cost treatments. Financing tools at clinics further support this trend by making expensive care more accessible at the decision point.High Out-of-Pocket Treatment Costs
Affordability remains a key challenge in the United States companion animal health market. High treatment costs delay wellness visits, reduce diagnostic follow-through, and limit specialist procedure adoption despite clinical demand. Missed routine visits impact service revenue and related product sales. Specialty care faces the greatest pressure as costs outpace household budgets, restricting access to premium offerings. Without broader insurance and financing options, out-of-pocket expenses will continue to constrain growth outside higher-income households.Other drivers and restraints analyzed in the detailed report include:
- AI-Enabled Diagnostics and Workflow Integration
- Vector-Borne Disease Preparedness and Screwworm Resilience
- Consolidator Formulary Discipline and Online Pharmacy Competition
Segment Analysis
In 2025, dogs held 59.35% of the United States companion animal health market share, driven by higher treatment frequency in areas like orthopedics, dental care, and cardiology. The adoption of biologic therapies further boosted revenue, with over 1 million dogs treated with Librela by early 2025, showcasing the rapid scaling of high-value pain management products. Dogs remain the primary revenue anchor, even as growth stabilizes.Cats are projected to grow at an 11.15% CAGR from 2026 to 2031, making them the fastest-growing segment in the United States companion animal health market. This growth is supported by species-specific innovations, such as a feline liquid biopsy prototype with 97% specificity for lymphoma detection and the launch of RapidRead Dental for Feline. Equine and other companion animals maintain stable demand through preventive care and specialized treatments.
Therapeutics accounted for 43.25% of the United States companion animal health market revenue in 2025, benefiting from new approvals and label expansions for chronic and specialty conditions. Key developments include VETMEDIN's clearance for preclinical myxomatous mitral valve disease and NUMELVI's approval for managing pruritus in dogs. The focus is shifting toward pain management, monoclonal antibodies, and chronic disease treatments.
Diagnostics is forecast to grow at a 12.75% CAGR from 2026 to 2031, becoming the fastest-growing product category. Clinics are adopting tools that streamline workflows, such as SDMA kidney biomarker testing integrated into Catalyst chemistry profiles. While digital health platforms are emerging, diagnostics stands out as a key driver of revenue growth through workflow integration.
Complete Report Scope:
- By Animal Type
- Dogs
- Cats
- Equine
- Other Companion Animals
- By Product Type
- Therapeutics
- Vaccines
- Parasiticides
- Anti-Infectives
- NSAIDs & Pain Management
- Monoclonal Antibodies
- Medical Feed Additives
- Other Therapeutics
- Diagnostics
- Immunodiagnostic Tests
- Molecular Diagnostics
- Diagnostic Imaging
- Point-of-Care Devices
- Other Diagnostics
- Digital Health & Services
- Tele-medicine Platforms
- Practice-Management Software
- Wearable Monitoring Devices
- Therapeutics
- By Indication
- Infectious Diseases
- Dermatology/Allergy
- Pain & Inflammation
- Endocrine & Metabolic Disorders
- Oncology
- Cardiology
- Others
- By Distribution Channel
- Veterinary Hospital and Clinic Pharmacies
- Retail Pharmacies
- E-commerce and Online Pharmacies
- Others
List of Companies Covered in this Report:
- Anivive Lifesciences, Inc.
- Antech Diagnostics
- Bimeda
- Boehringer Ingelheim Animal Health USA Inc.
- Cencora, Inc. (MWI Animal Health)
- Ceva Animal Health, LLC
- Covetrus
- Dechra Veterinary Products LLC
- Elanco
- HIPRA USA, Inc.
- IDEXX
- Intervet Inc. d/b/a Merck Animal Health
- Mars, Incorporated (Science & Diagnostics)
- Norbrook, Inc.
- Nutramax Laboratories Veterinary Sciences, Inc.
- Patterson Companies, Inc. (Patterson Veterinary)
- PetIQ, LLC
- Vetoquinol USA, Inc.
- Virbac S.A.
- Zoetis
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Anivive Lifesciences, Inc.
- Antech Diagnostics
- Bimeda, Inc.
- Boehringer Ingelheim Animal Health USA Inc.
- Cencora, Inc. (MWI Animal Health)
- Ceva Animal Health, LLC
- Covetrus, Inc.
- Dechra Veterinary Products LLC
- Elanco Animal Health Incorporated
- HIPRA USA, Inc.
- IDEXX Laboratories, Inc.
- Intervet Inc. d/b/a Merck Animal Health
- Mars, Incorporated (Science & Diagnostics)
- Norbrook, Inc.
- Nutramax Laboratories Veterinary Sciences, Inc.
- Patterson Companies, Inc. (Patterson Veterinary)
- PetIQ, LLC
- Vetoquinol USA, Inc.
- Virbac S.A.
- Zoetis Inc.
